OBJECTIVE:Lithium salts, once the mainstay of therapy for bipolar disorder, have tolerability issues at a higher dosage that often limit adherence. The authors investigated the comparative effectiveness of more tolerable dosages of lithium as part of optimized personalized treatment (OPT). METHOD: The authors randomly assigned 283 bipolar disorder outpatients to 6 months of open, flexible, moderate dosages of lithium plus OPT or to 6 months of OPT alone. The primary outcome measures were the Clinical Global Impression Scale for Bipolar Disorder-Severity (CGI-BP-S) and "necessary clinical adjustments" (medication adjustments per month). Secondary outcome measures included mood symptoms and functioning. The authors also assessed sustained remission (defined as a CGI-BP-S score ≤2 for 2 months) and treatment with second-generation antipsychotics. The authors hypothesized that lithium plus OPT would result in greater clinical improvement and fewer necessary clinical adjustments. RESULTS: The authors observed no statistically significant advantage of lithium plus OPT on CGI-BP-S scores, necessary clinical adjustments, or proportion with sustained remission. Both groups had similar outcomes across secondary clinical and functional measures. Fewer patients in the lithium-plus-OPT group received second-generation antipsychotics compared with the OPT-only group (48.3% and 62.5%, respectively). CONCLUSIONS: In this pragmatic comparative effectiveness study, a moderate but tolerated dosage of lithium plus OPT conferred no symptomatic advantage when compared with OPT alone, but the lithium-plus-OPT group had less exposure to second-generation antipsychotics. Only about one-quarter of patients in both groups achieved sustained remission of symptoms. These findings highlight the persistent and chronic nature of bipolar disorder as well as the magnitude of unmet needs in its treatment.
RCT Entities:
OBJECTIVE:Lithium salts, once the mainstay of therapy for bipolar disorder, have tolerability issues at a higher dosage that often limit adherence. The authors investigated the comparative effectiveness of more tolerable dosages of lithium as part of optimized personalized treatment (OPT). METHOD: The authors randomly assigned 283 bipolar disorder outpatients to 6 months of open, flexible, moderate dosages of lithium plus OPT or to 6 months of OPT alone. The primary outcome measures were the Clinical Global Impression Scale for Bipolar Disorder-Severity (CGI-BP-S) and "necessary clinical adjustments" (medication adjustments per month). Secondary outcome measures included mood symptoms and functioning. The authors also assessed sustained remission (defined as a CGI-BP-S score ≤2 for 2 months) and treatment with second-generation antipsychotics. The authors hypothesized that lithium plus OPT would result in greater clinical improvement and fewer necessary clinical adjustments. RESULTS: The authors observed no statistically significant advantage of lithium plus OPT on CGI-BP-S scores, necessary clinical adjustments, or proportion with sustained remission. Both groups had similar outcomes across secondary clinical and functional measures. Fewer patients in the lithium-plus-OPT group received second-generation antipsychotics compared with the OPT-only group (48.3% and 62.5%, respectively). CONCLUSIONS: In this pragmatic comparative effectiveness study, a moderate but tolerated dosage of lithium plus OPT conferred no symptomatic advantage when compared with OPT alone, but the lithium-plus-OPT group had less exposure to second-generation antipsychotics. Only about one-quarter of patients in both groups achieved sustained remission of symptoms. These findings highlight the persistent and chronic nature of bipolar disorder as well as the magnitude of unmet needs in its treatment.
Authors: Dominic Hodgkin; Elizabeth L Merrick; Peggy L O'Brien; Thomas G McGuire; Sue Lee; Thilo Deckersbach; Andrew A Nierenberg Journal: J Affect Disord Date: 2016-06-21 Impact factor: 4.839
Authors: Robert M Post; Lori L Altshuler; Gabriele S Leverich; Willem A Nolen; Ralph Kupka; Heinz Grunze; Mark A Frye; Trisha Suppes; Susan L McElroy; Paul E Keck; Mike Rowe Journal: Prim Care Companion CNS Disord Date: 2014-12-18
Authors: Michael J Ostacher; Andrew A Nierenberg; Dustin Rabideau; Noreen A Reilly-Harrington; Louisa G Sylvia; Alexandra K Gold; Leah W Shesler; Terence A Ketter; Charles L Bowden; Joseph R Calabrese; Edward S Friedman; Dan V Iosifescu; Michael E Thase; Andrew C Leon; Madhukar H Trivedi Journal: J Psychiatr Res Date: 2015-10-09 Impact factor: 4.791
Authors: Jodi Gonzalez Arnold; Stephanie Salcedo; Terrence A Ketter; Joseph R Calabrese; Dustin J Rabideau; Andrew A Nierenberg; Melissa Bazan; Andrew C Leon; Edward S Friedman; Dan Iosifescu; Louisa G Sylvia; Michael Ostacher; Michael Thase; Noreen A Reilly-Harrington; Charles L Bowden Journal: J Affect Disord Date: 2015-03-14 Impact factor: 4.839
Authors: Vicki C Fung; Lindsay N Overhage; Louisa G Sylvia; Noreen A Reilly-Harrington; Masoud Kamali; Keming Gao; Richard C Shelton; Terence A Ketter; William V Bobo; Michael E Thase; Joseph R Calabrese; Mauricio Tohen; Thilo Deckersbach; Andrew A Nierenberg Journal: J Affect Disord Date: 2019-07-02 Impact factor: 4.839
Authors: Dustin J Rabideau; Andrew A Nierenberg; Louisa G Sylvia; Edward S Friedman; Charles L Bowden; Michael E Thase; Terence A Ketter; Michael J Ostacher; Noreen Reilly-Harrington; Dan V Iosifescu; Joseph R Calabrese; Andrew C Leon; David A Schoenfeld Journal: Clin Trials Date: 2014-05-28 Impact factor: 2.486